日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial

老年人连续接种增强型流感疫苗后抗神经氨酸酶抗体反应:一项随机对照试验

Daulagala, Pavithra; Leung, Yonna W Y; Luk, Leo L H; Ho, Faith; Chu, Sofia H N; Lin, Jing; Cheng, Samuel M S; Leung, Nancy H L; Eichelberger, Maryna C; Peiris, Malik; Iuliano, A Danielle; Thompson, Mark G; Cowling, Benjamin J; Yen, Hui-Ling

Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents

青少年皮内注射与肌肉注射相比,对CoronaVac疫苗产生更优的抗体和膜蛋白特异性T细胞反应

Rosa Duque, Jaime S; Cheng, Samuel M S; Cohen, Carolyn A; Leung, Daniel; Wang, Xiwei; Mu, Xiaofeng; Chung, Yuet; Lau, Tsun Ming; Wang, Manni; Zhang, Wenyue; Zhang, Yanmei; Wong, Howard H W; Tsang, Leo C H; Chaothai, Sara; Kwan, Tsz Chun; Li, John K C; Chan, Karl C K; Luk, Leo L H; Ho, Jenson C H; Li, Wing Yan; Lee, Amos M T; Lam, Jennifer H Y; Chan, Sau Man; Wong, Wilfred H S; Tam, Issan Y S; Mori, Masashi; Valkenburg, Sophie A; Peiris, Malik; Tu, Wenwei; Lau, Yu Lung

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination

在接种同源BNT162b2或BNT162b2(WT + BA.4/5)二价加强疫苗的未感染个体中,针对SARS-CoV-2新出现的Omicron亚型的交叉中和抗体

Cheng, Samuel M S; Mok, Chris K P; Li, John K C; Chan, Ken K P; Luk, Kristine S; Lee, Ben H W; Gu, Haogao; Chan, Karl C K; Tsang, Leo C H; Yiu, Karen Y S; Ling, Ken K C; Tang, Yun Sang; Luk, Leo L H; Yu, Jennifer K M; Pekosz, Andrew; Webby, Richard J; Cowling, Benjamin J; Hui, David S C; Peiris, Malik

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial

比较使用 CoronaVac 和 BNT162b2 (Cobovax) 进行同源和异源加强免疫的抗体和细胞介导免疫反应、反应原性和疗效:一项开放标签、随机试验

Leung, Nancy H L; Cheng, Samuel M S; Cohen, Carolyn A; Martín-Sánchez, Mario; Au, Niki Y M; Luk, Leo L H; Tsang, Leo C H; Kwan, Kelvin K H; Chaothai, Sara; Fung, Lison W C; Cheung, Alan W L; Chan, Karl C K; Li, John K C; Ng, Yvonne Y; Kaewpreedee, Prathanporn; Jia, Janice Z; Ip, Dennis K M; Poon, Leo L M; Leung, Gabriel M; Peiris, J S Malik; Valkenburg, Sophie A; Cowling, Benjamin J

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine

在接种过两剂灭活疫苗的成年人中,第三剂BNT162b2对祖先型严重急性呼吸综合征冠状病毒2和Omicron变异株的免疫原性

Leung, Nancy H L; Cheng, Samuel M S; Martín-Sánchez, Mario; Au, Niki Y M; Ng, Yvonne Y; Luk, Leo L H; Chan, Karl C K; Li, John K C; Leung, Yonna W Y; Tsang, Leo C H; Chaothai, Sara; Kwan, Kelvin K H; Ip, Dennis K M; Poon, Leo L M; Leung, Gabriel M; Peiris, J S Malik; Cowling, Benjamin J

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents.

健康青少年接种第三剂灭活 COVID-19 疫苗后对野生型和 Omicron SARS-CoV-2 的免疫原性

Leung Daniel, Cohen Carolyn A, Mu Xiaofeng, Rosa Duque Jaime S, Cheng Samuel M S, Wang Xiwei, Wang Manni, Zhang Wenyue, Zhang Yanmei, Tam Issan Y S, Lam Jennifer H Y, Chan Sau Man, Chaothai Sara, Kwan Kelvin K H, Chan Karl C K, Li John K C, Luk Leo L H, Tsang Leo C H, Chu Nym Coco, Wong Wilfred H S, Mori Masashi, Leung Wing Hang, Valkenburg Sophie, Peiris Malik, Tu Wenwei, Lau Yu Lung

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.

青少年接种第三剂 BNT162b2 后,针对野生型和 Omicron SARS-CoV-2 的抗体和 T 细胞反应

Mu Xiaofeng, Cohen Carolyn A, Leung Daniel, Rosa Duque Jaime S, Cheng Samuel M S, Chung Yuet, Wong Howard H W, Lee Amos M T, Li Wing Yan, Tam Issan Y S, Lam Jennifer H Y, Lee Derek H L, Chan Sau Man, Tsang Leo C H, Chan Karl C K, Li John K C, Luk Leo L H, Chaothai Sara, Kwan Kelvin K H, Chu Nym Coco, Mori Masashi, Jeevan Trushar, Kandeil Ahmed, Webby Richard J, Tu Wenwei, Valkenburg Sophie A, Peiris Malik, Lau Yu Lung

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

接种同源和异源CoronaVac或BNT162b2疫苗后,针对SARS-CoV-2 Omicron变异株BA.1的中和抗体

Cheng, Samuel M S; Mok, Chris Ka Pun; Leung, Yonna W Y; Ng, Susanna S; Chan, Karl C K; Ko, Fanny W; Chen, Chunke; Yiu, Karen; Lam, Bosco H S; Lau, Eric H Y; Chan, Ken K P; Luk, Leo L H; Li, John K C; Tsang, Leo C H; Poon, Leo L M; Hui, David S C; Peiris, Malik

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

作者更正:SARS-CoV-2疫苗BNT162b2和CoronaVac在健康青少年中的免疫原性和反应原性

Rosa Duque, Jaime S; Wang, Xiwei; Leung, Daniel; Cheng, Samuel M S; Cohen, Carolyn A; Mu, Xiaofeng; Hachim, Asmaa; Zhang, Yanmei; Chan, Sau Man; Chaothai, Sara; Kwan, Kelvin K H; Chan, Karl C K; Li, John K C; Luk, Leo L H; Tsang, Leo C H; Wong, Wilfred H S; Cheang, Cheuk Hei; Hung, Timothy K; Lam, Jennifer H Y; Chua, Gilbert T; Tso, Winnie W Y; Ip, Patrick; Mori, Masashi; Kavian, Niloufar; Leung, Wing Hang; Valkenburg, Sophie; Peiris, Malik; Tu, Wenwei; Lau, Yu Lung